New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs for millions of people.

Galcanezumab shows similar pregnancy outcomes to placebo, highlighting the need for more real-world safety data in patients ...

Once-daily rimegepant 75 mg is effective and well-tolerated for short-term prevention of fasting-related headache in adults ...

If you’re craving salt, it may be because you're feeling bored or stressed, but it could be a sign of a nutritional ...

Expert Rev Clin Pharmacol. 2013;6(3):271-288. All FDA-approved migraine treatments are approved only for adults. No migraine products have officially been approved for use in children. Other types ...

Despite equally high prevalence of migraine in Asia as compared western countries, significant unmet needs remain in terms of sufficient and appropriate diagnosis, and better management and ...

Other secondary and exploratory endpoints assessed monthly migraine days over weeks 1-12, MOH remission, transition from chronic to episodic migraine, reductions in headache-related burden ...

In the SUNRISE trial, patients receiving eptinezumab experienced significantly fewer monthly migraine days (MMDs), with eptinezumab offering a -7.5 (300 mg) and -7.2 (100 mg) reduction in MMDs ...

Chronic migraine was defined as migraine occurring on ≥8 days per month and headache occurring on >14 days. Participants were randomly allocated to one of three treatment groups: eptinezumab 300 ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically significant ...

AbbVie beat out a competitor's migraine-fighting drug in terms of dose tolerability in a head-to-head study. The North Chicago-based drugmaker said its Phase 3 study of atogepant (Qulipta) in a ...